Ialuset cream is based on a formulation containing high molecular weight hyaluronic acid, dosed at 0.2%. This active ingredient, produced by Laboratoires Genevrier, was initially developed for the treatment of wounds and burns. Its off-label use as a daily cosmetic care raises pharmacovigilance questions that we address here from a clinical and regulatory perspective.
Regulatory distinction within the Ialuset range
The Ialuset range does not form a homogeneous block in terms of reimbursement. This is a point that most consumer articles overlook, creating persistent confusion among patients.
See also : All the automotive news: trends, reviews, and innovations in the auto industry
Ialuset Plus cream (silver sulfadiazine + hyaluronic acid) has been delisted for second-degree burns. The decision, made after reevaluation by the HAS, resulted in the product being removed from the list of reimbursable specialties for this indication.
Meanwhile, some medical devices in the range remain listed on the List of Products and Services (LPP). Ialuset Absorb Fine, an impregnated dressing intended for chronic wounds (leg ulcers, pressure sores), was the subject of an opinion from the CNEDiMTS in 2021. The commission recognizes it as having a sufficient medical benefit for these indications, which maintains its coverage.
Further reading : The Latest Web Trends: News, Innovations, and Tips for Geek Enthusiasts
Here we find detailed information regarding the reimbursement and reviews of Ialuset cream that clarify the current conditions of prescription.
The nuance to remember: a patient who presents at the pharmacy with a prescription for Ialuset cream (without the “Plus” mention) for a chronic wound does not fall under the same framework as a patient requesting Ialuset Plus for a superficial burn. The former may still benefit from coverage, while the latter does not.
Topical hyaluronic acid: real effectiveness on healing
Hyaluronic acid at 0.2% primarily acts by hydrating the wound bed. It promotes cell migration and neoangiogenesis in the early phases of healing. These properties are documented and undisputed.
However, the HAS, through the CNEDiMTS, concluded that there is no improvement in medical benefit (ASMR) compared to existing alternatives (hydrocellular dressings, hydrocolloids). Ialuset is considered a relevant option but not superior in terms of clinical effectiveness.
This positioning has concrete consequences for the prescriber. We recommend Ialuset in the following situations, where its galenic profile (cream or dressing) offers a practical advantage:
- Low exudative wounds requiring hydration at the wound bed, where a hydrocolloid would be oversized
- Anatomical areas that are difficult to dress (folds, mobile areas) where the cream allows for direct application without cutting a dressing
- Post-radiation epithelialitis, an indication in which a randomized trial (cancer registry.fr) compared hyaluronic acid to a simple emollient
Outside of these contexts, the choice between Ialuset and a next-generation dressing is more a matter of caregiver preference than demonstrated superiority.
Cosmetic misuse of Ialuset cream: what dermatologists say
The enthusiasm for Ialuset cream as an anti-aging or daily facial moisturizer constitutes a textbook case of medication misuse. Social media, led by TikTok, fuels this trend with testimonials from users praising skin that is “more supple, softer” from the first applications.
Ialuset cream remains a medication, not a cosmetic. Its formulation was not designed for prolonged daily application on the face. Several technical points explain dermatologists’ reservations:
- The galenic base contains excipients (liquid paraffin, petroleum jelly) that are comedogenic on mixed to oily skin, potentially causing acne breakouts
- The 0.2% hyaluronic acid in an occlusive base does not penetrate the epidermis in the same way as a cosmetic serum formulated with varying molecular weights
- The absence of sun filters and antioxidants in the formula makes the product incomplete as a day care, unlike dermocosmetic moisturizers
- Prolonged use outside of indication is not subject to any specific pharmacovigilance monitoring, and long-term adverse effects on healthy skin remain poorly documented
The price argument (around eight euros in pharmacies, reimbursed with a prescription for validated indications) partly explains the phenomenon. Some patients obtain a prescription for cosmetic use, which raises a public health expenditure issue when the product is covered.
Ialuset on prescription: prescription conditions and coverage
The prescription of Ialuset cream (hyaluronic acid alone, without sulfadiazine) for superficial wounds and burns remains possible. The doctor must specify the indication on the prescription so that the pharmacist can verify compliance with reimbursement conditions.
For the medical devices in the range (impregnated dressings, Absorb Fine), listing on the LPP conditions reimbursement. The coverage rate depends on the indication and the associated LPP code. A renewal without reevaluation of the wound by the prescriber is not compliant with HAS recommendations.
Ialuset Plus, combining silver sulfadiazine and hyaluronic acid, is no longer reimbursed for second-degree burns. Patients treated for burns must now bear the cost or turn to covered alternatives.
The regulatory framework of Ialuset illustrates a frequent reality in dermatology: the same active ingredient can be relevant in a targeted indication and unnecessary (even counterproductive) in an off-label use. The distinction between medication and cosmetic remains the most reliable guideline for directing patients.